Clinical metagenomics with nanopore sequencing involves more than running a MinION and piping the output through a classifier. Each stage of the workflow — from specimen collection through result delivery — introduces quality determinants that compound. A poorly chosen extraction method degrades everything downstream. A basecalling model not tuned for clinical isolates introduces systematic errors that propagate through alignment. Understanding where quality is made or lost in each stage is essential for laboratories designing a clinically deployable workflow.
Stage 1: Specimen handling and nucleic acid extraction
Nanopore sequencing is more sensitive to DNA fragmentation than short-read sequencing. Long reads require long DNA molecules — heavily fragmented DNA produces short reads that are harder to classify at species level and accumulate quickly in a way that can dominate sequencing output with low-information data. For the clinical metagenomics workflow, this means specimen handling from collection to extraction must minimize mechanical shearing.
For normally sterile specimens (blood, CSF, joint fluid), spin column-based extraction is generally acceptable if performed promptly after specimen receipt. For non-sterile specimens with high background — respiratory specimens, wound specimens — host DNA depletion is an important consideration. Without depletion, human DNA can represent 90–99% of sequencing reads in a respiratory specimen, consuming flow cell pore capacity and making pathogen reads a small fraction of total output. Saponin-based selective lysis and methylation-sensitive restriction enzyme digestion are both used for host depletion in clinical metagenomic workflows, with tradeoffs in organism recovery and throughput.
Library preparation for rapid clinical workflows typically uses ligation-based rapid kits that work with fragmented DNA and can be completed in 10–15 minutes. Barcoding enables multiplexing of multiple specimens per run when specimen volume allows — a practical consideration for throughput, though multiplexing adds demultiplexing steps downstream and can introduce barcode bleed-through if not managed carefully.
Stage 2: Sequencing and real-time read generation
The flow cell itself is a consumable with finite pore count and a characteristic run profile: pore count is highest at run start and declines over time as pores become blocked or inactive. For a clinical 30–45 minute run, the run is operating near peak pore availability — not like a 72-hour research run that has degraded pore count in its later phases.
Flow cell loading quality has a significant effect on read length and yield. Under-loading produces fewer reads; over-loading blocks pores rapidly. Target input for a rapid clinical run is typically 1–5 ng of genomic DNA for a standard rapid library prep. For very low-biomass specimens, this input requirement is a real constraint — CSF from a patient with early meningitis may not reliably provide 1 ng of pathogen DNA, and the workflow must account for the possibility of insufficient input generating an uninformative "below detection threshold" result rather than a false negative.
Sequencing parameters for clinical workflows differ from research settings. Minimum base quality filtering, read length minimums, and real-time basecalling settings should all be locked to the validated configuration. Allowing individual operators to adjust run parameters introduces inter-operator variability that CLIA validation won't have characterized.
Stage 3: Basecalling — the quality multiplier
Basecalling is the stage where the most consequential software quality decisions are made. As covered separately in our article on adaptive basecalling, the model choice, compute architecture, and real-time versus batch processing mode all affect the quality of reads available for downstream analysis.
For the metagenomics workflow specifically, basecalling quality affects two distinct downstream functions: organism identification (where 16S and other marker gene accuracy is most critical) and AMR gene detection (where resistance locus accuracy is most critical). These two functions have partially different error tolerance profiles, and a basecalling model should be evaluated against both, not just overall Q-score.
Demultiplexing — assigning reads to specimens when multiple are loaded on a single flow cell — is conceptually part of the basecalling stage. Barcode classification quality degrades with low-quality reads and can be miscalled for reads near the quality threshold. The clinical pipeline must have a defined minimum barcode classification score and handle unclassified reads explicitly rather than silently discarding them.
Stage 4: Taxonomic classification and pathogen identification
Reads passing quality filters enter the taxonomic classification stage. Multiple algorithmic approaches exist: k-mer-based classifiers (fast, lower sensitivity for divergent organisms), marker gene alignment (slower, higher specificity for identification-relevant loci), and full read-level alignment against curated pathogen databases.
For clinical use, speed and specificity both matter. A false positive pathogen identification — reporting an organism that is not causing infection — can lead to unnecessary treatment or delay the search for the true pathogen. A false negative — failing to identify a present pathogen — may leave the patient on empiric therapy inappropriately. The reference database quality is as important as the classification algorithm: a database containing misassembled or contaminated reference sequences will produce spurious classifications regardless of algorithm quality.
Confidence scoring at the identification stage must quantify both the evidence strength (how many reads, from how many genomic regions, support the identification) and the classification certainty (how clearly the read alignments distinguish the identified organism from related species). These two dimensions of confidence should be reported separately, because a high-read-count identification with low-certainty alignment is a different clinical situation from a low-read-count identification with high-certainty alignment.
Stage 5: AMR gene detection and resistance profiling
AMR gene detection from metagenomic data requires alignment against a curated AMR gene database (CARD, ResFinder, and NCBI AMR are commonly used reference sets) and interpretation of alignment results in the context of read quality and coverage depth.
Critical issues specific to nanopore reads: the raw error rate makes short AMR gene segments harder to call with confidence (a 500 bp resistance gene covered by 10× nanopore reads with 8% per-base error requires careful confidence modeling); frameshifted reads caused by homopolymer indel errors can suggest truncated/non-functional resistance genes when the gene is intact; and plasmid-borne resistance genes require sufficient read depth across the plasmid backbone to confirm the chromosomal versus plasmid context, which has clinical significance for transmission risk assessment.
The AMR report delivered to the clinical team should clearly distinguish between confirmed gene presence (high-coverage, high-confidence alignment) and provisional detection (low-coverage or low-confidence, requiring confirmatory testing). The pipeline must not present a low-confidence resistance gene call at the same visual weight as a high-confidence one — these have different clinical implications and must be differentiated in the report.
Stage 6: Result formatting and LIS delivery
The final stage translates the analytical outputs — organism identification, confidence scores, AMR flags — into a clinically interpretable report and delivers it to the LIS where the ordering physician will see it. This stage is frequently underestimated in complexity.
The clinical report must balance completeness with interpretability. A metagenomic run may identify dozens of organisms at varying confidence levels. The report should highlight clinically actionable findings (high-confidence priority pathogen identification, confirmed resistance gene detections) while making lower-confidence and low-relevance findings available for review without cluttering the primary result view.
HL7 v2 ORU message formatting for genomic results requires mapping organism names to LOINC and SNOMED codes, resistance findings to appropriate result coding, and confidence scores to interpretive comments. This is non-trivial vocabulary work that differs from standard culture result formatting, and the LIS interface team will encounter it as a new problem even if they have extensive HL7 experience with conventional microbiology results. Structured result delivery from the pipeline significantly reduces the burden on the LIS integration layer.